Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis

NCT01742585 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01742585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01742585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2012
Completion date
May 31, 2014
Enrollment
163 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, hyperphosphatemia, renal insufficiency